Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Pharmaceutical industry. | Image Credit: Africa Studio - stock.adobe.com
The Future of Pharmacy: Trends, Threats, Transformations

January 10th 2025

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.
Top 5 Biosimilar Articles of 2024

December 28th 2024

Paper with FDA approved on top of a magnifying glass and a keyboard | Image Credit: Pawel - stock.adobe.com
5 Key Drug Approvals and CRLs in 2024

December 27th 2024

FDA approval with stamp. | Image Credit: Surendra - stock.adobe.com
FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

December 20th 2024

AJMC
Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022

December 16th 2024

More News

Looking at Published Data and Implications of Interchangeability
August 5th 2022

Looking at Published Data and Implications of Interchangeability

Mariam Alboustani, PharmD, discusses the one published example of a switching study and the implications of interchangeability for pharmacists, as well as payers.
identical vials in a row
August 3rd 2022

Data Support Safety, Effectiveness of Biosimilar-to-Biosimilar Switching

Laura Joszt, MA
Although there is a paucity of data of switching among biosimilars of the same reference product, the few studies published support the safety and effectiveness of transitioning patients from one biosimilar to another.
Defining Interchangeable Biosimilars
July 29th 2022

Defining Interchangeable Biosimilars

Drs Kaddis and Oskouei define interchangeable biosimilars, their FDA requirements, and switching studies.
An Overview of Biosimilars and Future Agents
July 29th 2022

An Overview of Biosimilars and Future Agents

Atheer Kaddis, PharmD, and Sonia T. Oskouei, PharmD, BCMAS, DPLA, provide an overview of biosimilars and the preparation for future launches on the horizon.
insulin
July 21st 2022

California Initiative Provides $100 Million to Produce Its Own Insulin Biosimilars

Laura Joszt, MA
The budget allocates half of the money for the development of low-cost interchangeable insulin biosimilars and the other half for building an insulin manufacturing facility in the state.
map of europe
July 21st 2022

Medicines for Europe: Off-Patent Medicines Could Strengthen Europe’s Health Systems

Skylar Jeremias
During its annual conference in Spain, Medicines for Europe shared recommendations for greater use of off-patent medications, such as biosimilars and generics, as a way ensure medicines remain available to patients in light of global events and supply chain issues.
closed eye
July 19th 2022

Ophthalmologists See Promise and Peril, but Lack Familiarity, With Biosimilars

Laura Joszt, MA
Until recently, ophthalmologists in the United States have had no experience with biosimilars, despite the availability of biosimilars for bevacizumab, which is commonly used off label for ophthalmic conditions.
bone image
July 15th 2022

Denosumab Biosimilar Noninferior to Reference Product in Postmenopausal Women

Laura Joszt, MA
The study of postmenopausal women in Iran found the efficacy of the biosimilar was noninferior to the reference product and the safety was comparable after 18 months.
doctor giving a vaccine to an older woman
July 12th 2022

Most Patients Received Inadequate Information on Switching to Biosimilars, Survey Finds

Skylar Jeremias
A survey of patients with breast cancer and oncologists found that when switching to a trastuzumab biosimilar from the reference product (Herceptin), many patients were not given adequate information on what biosimilars are and their benefits.
rows of identical vials
July 7th 2022

Institutions Report Shift to Oncology Biosimilars in Pair of ASCO Abstracts

Laura Joszt, MA
The oncology space has seen successful adoption of biosimilars thanks to processes and formulary decisions driving conversion rates.
Colon
July 2nd 2022

Real-World Outcomes Explored in Studies of Bevacizumab Biosimilar for Metastatic Colorectal Cancer

Lindsey Mulrooney
Abstracts presented at the 2022 American Society of Clinical Oncology Annual Meeting show bevacizumab-awwb to be safe and effective for patients with metastatic colorectal cancer (mCRC) with high overall survival rates.
team of providers
July 1st 2022

The Role of APs in Integrating Biosimilars in Oncology Practice

AJMC Staff
Advanced practitioners (APs) have a role to play in strategies for integrating biosimilars into clinical practice.
Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds
June 24th 2022

Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds

Laura Joszt, MA
Among a real-world cohort of patients, switching between infliximab biosimilars was effective and well tolerated, although retention was higher among those who had initially started on the originator product.
cutting cost image
June 23rd 2022

Biosimilar Utilization Increased During the OCM and Generated Savings

Laura Joszt, MA
Abstracts presented at the American Society of Clinical Oncology Annual Meeting evaluated biosimilar use in practices participating in the Oncology Care Model (OCM) and estimated the savings as a result of substituting these agents for more expensive reference products.
insulin
June 16th 2022

Canadian Province Successfully Switches Patients to Insulin Glargine Biosimilar

Laura Joszt, MA
As part of the Biosimilars Initiative, British Columbia, Canada, implemented a mandatory switch to biosimilar insulin glargine for patients covered by the province’s drug plan.
elderly patient with doctor
June 10th 2022

Use of Rituximab Biosimilar With CHOP to Treat DLBCL Is Effective, EHA Abstracts Find

Laura Joszt, MA
Using biosimilar rituximab to replace the reference in a common combination regimen to treat diffuse large B-cell lymphoma (DLBCL) results in similar outcomes.
rows of identical vials
June 9th 2022

Studies on Switching Confirm Efficacy of Adalimumab Biosimilars

Laura Joszt, MA
Real-world studies evaluating the safety and efficacy of switching to adalimumab biosimilars from the originator product confirmed the safety and efficacy of the biosimilars ABP 501 and SB5.
fda logo
June 2nd 2022

FDA Approves Fifth Neulasta Biosimilar

Skylar Jeremias
The FDA approval for Fylnetra represents the fifth approval for a biosimilar referencing Neulasta (pegfilgrastim) in the United States.
row of identical vials
June 1st 2022

Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations

Laura Joszt, MA
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version.
Patient and doctor discussing record
May 29th 2022

Patient Experiences, Oncologist Perceptions Differ for Trastuzumab Biosimilar Switch

Laura Joszt, MA
Surveys of patients and oncologists found discrepancies between patient experiences and oncologist perceptions of those experiences during a nonmedical switch to trastuzumab biosimilars.
Sonia Oskouei, PharmD, of Cardinal Health
May 27th 2022

Dr Sonia Oskouei Highlights the Need to Align Incentives to Promote Use of Biosimilars

Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
cutting costs
May 26th 2022

Payer Management Tools and Trends for Biosimilars in the US

Laura Joszt, MA
As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents.
Sonia Oskouei, PharmD, of Cardinal Health
May 16th 2022

Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab Biosimilars

While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Image of a pharmacy
May 12th 2022

Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

Laura Joszt, MA
Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.
Doug Long of IQVIA
May 10th 2022

IQVIA’s Doug Long: Adalimumab Biosimilars Provide More Opportunity for Price Discounts

The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.
health care business and finances
May 4th 2022

340B, Biosimilars, and More in the Future of Specialty Pharmacy

Laura Joszt, MA
Adam Fein, PhD, of Drug Channels Institute, and Doug Long of IQVIA discussed trends in the specialty pharmacy market in the United States.
america graphic
May 3rd 2022

Gottlieb, Fein Discuss COVID-19, Accelerated Approvals, and Drug Pricing at Asembia 2022

Gianna Melillo
Scott Gottlieb, MD, and Adam Fein, PhD, discussed potential fallout of the FDA Aduhelm approval and lessons learned from the COVID-19 pandemic.
Doctor with father and child
April 30th 2022

Biosimilar Education Needed for Pediatric Patients With IBD and Caregivers

Laura Joszt, MA
Not only did a majority of each group say they hadn’t heard of biosimilars, but those who had heard of them had negative perceptions.
Gillian Woollett, MA, Dphil
April 29th 2022

Dr Gillian Woollett Highlights International Markets With Successful Biosimilar Adoption

Skylar Jeremias
Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.
Ryan Haumschild, PharmD, MS, MBA
April 23rd 2022

Ryan Haumschild, PharmD, Explains How Emory Healthcare Will Address the Influx of Humira Biosimilars in 2023

Skylar Jeremias
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.
<12345678910
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo